3 October 2022 (Monday) - Transfusion Evidence Alert Update

The nice people at “Transfusion Evidence Alert” sent their update today. They’ve now restricted themselves to ten articles. I must admit I find tat a lot less daunting…

TOP ARTICLES

Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature.Cajamarca-Barón, J., et al. (2022). Autoimmunity Reviews. [Record in Progress].

Predicting postpartum haemorrhage: A systematic review of prognostic models.Carr, B.L., et al. (2022). The Australian & New Zealand Journal of Obstetrics & Gynaecology. [Record in Progress].

The effect of motivational strategy on voluntary plasma donation, a field trial.Hajinasrollah, G., et al. (2022). Transfusion and Apheresis Science: official journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis. [Record in Progress].

Rotational thromboelastometry guided blood component use in cirrhotic children undergoing invasive procedures: Randomized Controlled Trial.Maria, A., et al. (2022). Liver International: Official Journal of the International Association for the Study of the Liver.

Desmopressin Acetate in Percutaneous Ultrasound-Guided Native Kidney Biopsy in Patients with Reduced Kidney Function: A Double-Blind Randomized Controlled Trial.Sattari, S.A., et al. (2022). Iranian Journal of Kidney Diseases.

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.Taher, A.T., et al. (2022). The Lancet. Haematology. [Record in Progress].

An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial.Thomson, P.C., et al. (2022). Kidney International Reports.

Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial.Gharbharan, A., et al. (2022). Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. [Record in Progress].

Hyperimmune globulin for severely immunocompromised patients hospitalized with COVID-19: a randomized, controlled trial.Huygens, S., et al. (2022). The Journal of Infectious Diseases. [Record in Progress].

ARTICLE OF THE MONTH

Prophylactic Use of Antifibrinolytics During Pediatric Cardiac Surgery With Cardiopulmonary Bypass on Postoperative Bleeding and Transfusion: A Systematic Review and Meta-Analysis.Schertz, K., et al. (2022). Pediatric Critical Care Medicine: A Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. [Record in Progress].PICO Summary available

+++++


 

30 September 2022 (Friday) -Transfusion News Update

The nice people at “Transfusion News” sent their update today. As always, all good stuff…

Iron Repletion Does Not Effect Donor Well-Being or Red Cell Quality

Transfusion News Image 1
September 28, 2022
Iron deficiency develops in over one third of regular, repeat blood donors. In order to exam the physiological consequences of iron deficiency in blood donors, a randomized, double-blind, placebo-controlled trial (Donor Iron Deficiency Study [DIDS]) screened 2,011 adult blood donors. [Read More]
 
 
FROM OUR SPONSOR
Join us to hear about sickle cell disease and the risk of hemolytic transfusion reactions
Transfusion News Image 1
In this new Transfusion Science Webinar, Karina Yazdanbakhsh, PhD, will discuss our current understanding of hemolytic transfusion reactions (HTR) in patients with sickle cell disease, with a focus on potential pathophysiologic mechanisms, recommended approaches to managing HTR, and strategies to prevent the development of HTR. [Register Now]
 
 



Sickle Cell Disease Advocacy- Live Twitter Space Event Today
Transfusion News Image 1
Join Transfusion News Associate Editors Daniela Hermelin and Monica Pagano on Twitter Space this Friday September 30 at 11:00 AM ET for a #Blooducation Baristas live event. Dr. Hermelin and Dr. Pagano will be joined by Richard Godby, Tiffani Skinner-Jackson and Patrick McGann to discuss Sickle Cell Disease Advocacy. [Set a reminder to join us]
 
 
Prophylactic Tranexamic Acid Does Not Decrease Bleeding or Transfusions in Patients with Hematologic Malignancies
Transfusion News Image 1
September 21, 2022
Patients with hematologic malignancies account for 43% of the 2 million platelet doses transfused in the U.S. each year. Despite prophylactic platelet transfusions, 43% of patients with hematologic malignancies still experience WHO grade 2 bleeding or higher. Tranexamic acid (TXA) is commonly used to prevent bleeding and mortality in a many patients including orthopedic, cardiothoracic, organ transplant, trauma, and obstetrical. [Read More]

 

29 September 2022 (Thursday) - UKAS Update

The United Kingdom Accreditation Service sent their update today – you can read it by clicking here. I read it…
I have mentioned before that I’m not “on board” with the United Kingdom Accreditation Service or with ISO 15189.
Call me reactionary if you will, but from what I can see, whilst some of it is useful, much of it is paperwork for paperwork’s sake.
We were far better off in the day with dedicated Clinical Pathology Accreditation when we had a system with us in mind. Now we have something supposedly applicable to a far wider catchment group, and the standards are incredibly  generic.
I so want to see the benefit of this…